Physician profile
Mark S Law
NPI 1275536237
$7,512.10
in general payments reported to CMS, 2019-2025
28 companies · $1,468 in 2025
The $1,468 reported for 2025 was more than what 84% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,121 · 2020: $95.79 · 2021: $15.80 · 2022: $870 · 2023: $1,073 · 2024: $1,869 · 2025: $1,468.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,409.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,409.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $1,217.03 | 2019-2024 | Tecnis Iol |
| Alcon Vision LLC | $876.10 | 2019-2025 | Clareon Panoptix Pro, Ngenuity, Clareon |
| Regeneron Healthcare Solutions, INC. | $724.63 | 2019-2025 | Eylea Hd, Eylea |
| Mallinckrodt Hospital Products INC. | $555.38 | 2022-2025 | Acthar |
| Abbvie INC. | $515.66 | 2022-2025 | |
| Allergan, INC. | $505.62 | 2019-2022 | |
| Tarsus Pharmaceuticals, INC. | $491.69 | 2024-2025 | Xdemvy |
| Bausch & Lomb Americas INC. | $388.21 | 2023-2025 | Miebo, Xiidra, Vyzulta |
| Dompe US, INC. | $324.16 | 2019-2025 | Oxervate |
| New World Medical,INC. | $239.14 | 2023-2025 | Kahook Dual Blade, Ahmed Glaucoma Valve, Clearpath |
| Oyster Point Pharma, INC. | $233.45 | 2022-2023 | Tyrvaya |
| Genentech USA, INC. | $215.26 | 2023-2025 | Susvimo, Vabysmo |
| Novartis Pharmaceuticals Corporation | $179.07 | 2019-2023 | |
| Aerie Pharmaceuticals, INC. | $168.08 | 2019-2020 | |
| Amgen INC. | $153.48 | 2024-2025 | Tepezza |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $121.18 | 2024 | Izervay |
| Horizon Therapeutics Plc | $115.11 | 2023 | Tepezza |
| Ocular Therapeutix, INC. | $105.74 | 2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $99.99 | 2019 | |
| Rayner Intraocular Lenses Limited | $80.86 | 2023-2025 | Omidria, Rayone Spheric, Rayone Aspheric |
| Apellis Pharmaceuticals, INC. | $45.01 | 2022-2023 | Syfovre |
| Sight Sciences, INC. | $40.05 | 2025 | Omni Surgical System |
| Sun Pharmaceutical Industries INC. | $29.51 | 2020 | |
| Biotissue Holdings INC. | $23.06 | 2023 | |
| Merz Pharmaceuticals, LLC | $18.26 | 2024 | Xeomin |
| Thea Pharma INC. | $16.31 | 2025 | Iyuzeh |
| Omeros Corporation | $16.09 | 2019 | |
| Harrow Eye, LLC | $13.97 | 2024 | Triesence, Iheezo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Law listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.